Categories: BionicNews

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings

Paris, France, January 17, 2024 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris – FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the Company as soon as it becomes aware of it.

Pixium draws investors’ attention to the fact that, given the price offered by the prospective buyer and the Company’s level of indebtedness, the sale proceeds received in the event of a favourable decision by the Commercial Court will not allow a total or partial reimbursement of shareholders.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information: http://www.pixium-vision.com/fr

Follow us on @PixiumVision; www.facebook.com/pixiumvision

               www.linkedin.com/company/pixium-vision  

Contacts

Investor Relations

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com

Media Relations

Rose Piquante Consulting
Sophie Baumont
Sophie.baumont@rosepiquante-consulting.com
+33 6 27 74 74 49

 

Attachment

Staff

Recent Posts

Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 4, 2026) - Izotropic Corporation (CSE:…

51 minutes ago

INTURAI VENTURES LAUNCHES NEW CAPABILITIES FOR HEALTHCARE AND SURVEILLANCE USING STANDARD WIRELESS SIGNALS

(CSE: URAI  / OTC: URAIF / FSE: 3QG0)investor@inturai.comHighlightsInternally developed processes enable biometric sensing and health…

3 hours ago

Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform

Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB:…

5 hours ago

In HelloNation, Immigration Attorney Maleeha Haq of Newark, CA, Explains How the Asylum Process Works for Immigrants

NEWARK, Calif., Feb. 3, 2026 /PRNewswire/ -- What steps must immigrants take to navigate the…

9 hours ago

Medexus Schedules Third Fiscal Quarter 2026 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP)…

15 hours ago

In HelloNation, Family Counseling Expert Scott Ostrowski of Geneva Outlines Employee and Employer Support Services for HelloNation

GENEVA, N.Y., Feb. 3, 2026 /PRNewswire/ -- What are Employee and Employer Support Services, and…

15 hours ago